• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2009 Fiscal Year Final Research Report

Functional study of leukemia-associated factor AML1

Research Project

  • PDF
Project/Area Number 17013091
Research Category

Grant-in-Aid for Scientific Research on Priority Areas

Allocation TypeSingle-year Grants
Review Section Biological Sciences
Research InstitutionNational Cancer Center Research Institute and Research Center for Innovative Oncology, National Cancer Center Hospital East

Principal Investigator

KITABAYASHI Issay  National Cancer Center Research Institute and Research Center for Innovative Oncology, National Cancer Center Hospital East, 分子腫瘍学部, 部長 (20261175)

Co-Investigator(Kenkyū-buntansha) SHIMIZU Kimiko  国立がんセンター(研究所及び東病院臨床開発センター), 分子腫瘍学部, 主任研究官 (00161414)
ROKUDAI Susumu  国立がんセンター(研究所及び東病院臨床開発センター), 分子腫瘍学部, 研究員 (20392334)
YOSHIDA Hitoshi  国立がんセンター(研究所及び東病院臨床開発センター), 分子腫瘍学部, 室長 (30303548)
Project Period (FY) 2005 – 2009
KeywordsAML1 / 白血病 / 造血 / タンパク質複合体 / 転写制御
Research Abstract

The AML1 gene is the most frequent target of chromosome translocations and other mutations in acute myeloid leukemia. We purified AML1 complex and found that the complex contained p300/CBP, MOZ, PML, and HIPK2 as well as CBFb. PML is a nuclear protein that functions as a regulator of transcription, cell proliferation, apoptosis, and myeloid cell differentiation. PML interacts with several transcription factors, such as AML1, PU.1, C/EBP and p53, as well as their co-activators, such as HIPK2 and p300, resulting in the activation of transcription. Although PML is thought to achieve transcription activation by stabilizing the transcription-factor complex, little is known about the underlying molecular mechanism. To clarify the role of PML in transcription regulation, PML complex was purified and Fbx3, Skp1, and Cullin1 were identified as novel components of this complex. Fbx3 formed SCFFbx3 ubiquitin ligase and promoted the degradation of HIPK2 and p300 by the ubiquitin-proteasome pathway. PML inhibited this degradation through a mechanism that unexpectedly did not involve inhibition of the ubiquitination of HIPK2. PML, Fbx3, and HIPK2 synergistically activated p53-induced transcription. Our findings suggest that PML stabilizes the transcription-factor complex by protecting HIPK2 and p300 from SCFFbx3-induced degradation until transcription is completed. In contrast, the leukemia-associated fusion PML-RAR α induced the degradation of HIPK2, suggesting that PML-RAR α degrade co-activators to block transcription by antagonizing PML.

  • Research Products

    (21 results)

All 2010 2009 2008 2007 2006 2005

All Journal Article (13 results) Presentation (6 results) Patent(Industrial Property Rights) (2 results)

  • [Journal Article] A Higher-Order Complex Containing AF4 and ENL Family Proteins with P-TEFb Facilitates Oncogenic and Physiologic MLL-Dependent Transcription.2010

    • Author(s)
      Yokoyama A, Lin M, Naresh A, Kitabayashi I, Cleary ML.
    • Journal Title

      Cancer Cell 17

      Pages: 198-212

  • [Journal Article] PU.1-mediated upregulation of M-CSFR is critical for leukemia stem cell potential induced by MOZ-TIF2.2010

    • Author(s)
      Aikawa Y, Katsumoto K, Zhang P, Shima H, Shino M, Terui K, Ito E, Ohno H, Stanley ER, Singh H, Tenen DG, Kitabayashi I.
    • Journal Title

      Nat Med 16

      Pages: 580-585

  • [Journal Article] MOZ interacts with p53 to induce p21 expression and cell-cycle arrest.2009

    • Author(s)
      Rokudai S, Aikawa Y, Tagata Y, Tsuchida N, Taya Y, Kitabayashi I.
    • Journal Title

      J Biol Chem. 284

      Pages: 237-244

  • [Journal Article] Sirt1 physically interacts with Tip60 and negatively regulates Tip60-mediated acetylation of H2AX.2009

    • Author(s)
      Yamagata K, Kitabayashi I.
    • Journal Title

      Biochem Biophys Res Commun 390

      Pages: 1355-1360

  • [Journal Article] Phosphorylation of PML is essential for activation of C/EBPe and PU. 1 to accelerate granulocytic differentiation.2008

    • Author(s)
      Tagata Y., Yoshida H, Nguyen LA, Kato H, Ichikawa H, Tashiro F, Kitabayashi I.
    • Journal Title

      Leukemia 22

      Pages: 273-280

  • [Journal Article] Roles of the histone acetyltransferase MOZ in normal and malignant hematopoiesis.2008

    • Author(s)
      Katsumoto T, Yoshida N, Kitabayashi I
    • Journal Title

      Cancer Sci. 99

      Pages: 1523-7

  • [Journal Article] PML activates transcription by protecting HIPK2 and p300 from SCF/Fbx3-mediated degradation.2008

    • Author(s)
      Shima Y, Shima T, Chiba T, Irimura T, Pandolfi PP, Kitabayashi I.
    • Journal Title

      Mol Cell Biol. 28

      Pages: 7126-7138

  • [Journal Article] Foxp3 controls regulatory T cell function via interacting with AML1/Runx1.2007

    • Author(s)
      Ono M, Yaguchi H, Ohkura N, Kitabayashi I, Nagamura Y, Nomura T, Miyachi Y, Tsukada T, Sakaguchi, S.
    • Journal Title

      Nature 446

      Pages: 685-689

  • [Journal Article] Mutations of the HIPK2 gene in acute myeloid leukemia and myelodysplastic syndrome impair AML1- and p53-mediated transcription.2007

    • Author(s)
      Li XL, Arai Y, Harada H, Shima Y, Yoshida H, Rokudai S, Aikawa Y, Kimura A, Kitabayashi I.
    • Journal Title

      Oncogene. 26

      Pages: 7231-7239

  • [Journal Article] PML-RARA inhibits PML IV enhancement of PU. 1-induced C/EBPe induced-expression in myeloid differentiation.2007

    • Author(s)
      Yoshida H, Ichikawa H, Tagata Y, Katsumoto T, Ohnishi K, Akao Y, Naoe T, Pandolfi PP, Kitabayashi I.
    • Journal Title

      Mol. Cell. Biol. 27

      Pages: 5819-5834

  • [Journal Article] MOZ is essential for maintenance of hematopoietic stem cells.2006

    • Author(s)
      Katsumoto T, Aikawa Y, Iwama A, Ueda S, Ichikawa H, Ochiya T, Kitabayashi I.
    • Journal Title

      Genes & Dev. 20

      Pages: 1321-1330

  • [Journal Article] Roles of HIPK1 and HIPK2 in AML1- and p300-dependent transcription, hematopoiesis and blood vessel formation.2006

    • Author(s)
      Aikawa Y, Nguyen LA, Isono K, Takakura N., Tagata Y, Schmitz ML, Koseki H, Kitabayashi I.
    • Journal Title

      EMBO J. 25

      Pages: 3955-3965

  • [Journal Article] Physical and functional link of the leukemiaassociated factors AML1 and PML.2005

    • Author(s)
      Nguyen LA, Pandolfi PP, Aikawa Y, Tagata Y, Ohki M, Kitabayashi I.
    • Journal Title

      Blood 105

      Pages: 292-300

  • [Presentation] The role of YB-1, a binding partner of nucleophosmin, in hematopoiesis and nucleophosmin mutant (NPMc)-associated acute myeloid leukemia.2010

    • Author(s)
      Yoko Ogawara, Takuo Katsumoto, Takeshi Uchiumi, Kimitoshi Kohno, Issay Kitabayashi
    • Organizer
      2010 AACR/JCR Joint Conference
    • Place of Presentation
      Hilton waikoloa Village in Hawaii, USA
    • Year and Date
      20100206-20100210
  • [Presentation] PU. 1-mediated upregulation of M-CSFR is critical for MOZ-leukemia stem cell potential2009

    • Author(s)
      Yukiko Aikawa1, Takuo Katsumoto1, Daniel G Tenen, Issay Kitabayashi1
    • Organizer
      51th annual meeting of American Society of Hemaology
    • Place of Presentation
      Ernest N. Merial Convention Center New Orleans
    • Year and Date
      20091205-20091208
  • [Presentation] Hemizygousity of AML1/RUNX1, a target of p53, prevents T-cell malignancy induced by loss of p532009

    • Author(s)
      Kimiko Shimizu, Issay Kitabayashi
    • Organizer
      Runx Meeting 2009
    • Place of Presentation
      Oxford University
    • Year and Date
      20090816-20090819
  • [Presentation] Roles of histone actyltransferases MOZ/MORF in hematopoiesis and leukemia2009

    • Author(s)
      Yukiko Aikawa, Takuo Katsumoto, Issay Kitabayashi
    • Organizer
      Runx Meeting 2009
    • Place of Presentation
      Oxford University
    • Year and Date
      20090816-20090819
  • [Presentation] Roles of histone actyltransferase MOZ in hematopoiesis and leukemia2009

    • Author(s)
      Issay Kitabayashi
    • Organizer
      FASEB Summer Research Coference on Histone
    • Place of Presentation
      Deacetylases and Reversible Acetylation in Signaling and Disease Il Ciocco Resort
    • Year and Date
      20090809-20090814
  • [Presentation] USA-Japan Cooperative Cancer Workshop on Stem Cells in Normal and Malignant Hematopoiesis2009

    • Author(s)
      Kitabayashi I.
    • Organizer
      OZ leukemic stem cells
    • Place of Presentation
      Hilton waikoloa Village in Hawaii, USA
    • Year and Date
      20090327-20090329
  • [Patent(Industrial Property Rights)] (Tharapeutic agent for MLL leukemia and MOZ leukemia of which molecular target is M-CSF receptor, and use thereof2008

    • Inventor(s)
      北林一生
    • Industrial Property Rights Holder
      国立がんセンター総長
    • Industrial Property Number
      PCT・JP2008/072609
    • Filing Date
      2008-12-12
    • Acquisition Date
      2009-06-18
  • [Patent(Industrial Property Rights)] M-CSF受容体を分子標的とするMLL白血病及びMOZ白血病治療剤、およびその利用2007

    • Inventor(s)
      北林一生
    • Industrial Property Rights Holder
      国立がんセンター総長
    • Industrial Property Number
      特願・2007-321256
    • Filing Date
      2007-12-12
    • Acquisition Date
      2007-12-12

URL: 

Published: 2011-06-18   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi